Nanosonics
ASX:NAN Community- 1 Narratives written by author
- 1 Comments on narratives written by author
- 43 Fair Values set on narratives written by author
WA
Consensus Narrative from 10 Analysts
CORIS FDA Filing Will Set New Standard In Endoscopy Reprocessing
Key Takeaways Strategic growth in high-margin recurring revenue and further North American market penetration in the trophon business suggest enhanced revenue and net margins. Regulatory advancements and increased R&D investment could lead to revenue growth, improved diversification, and better net earnings.
View narrativeAU$3.56
FV
2.7% undervalued intrinsic discount10.82%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
10 days ago author updated this narrative